Study the pathological featureS of diSeaSeS uSing induced pluripotent Stem cellS derived form patient'S Somatic cellS
The limited experimental acceSS to diSeaSe-affected human tiSSueS haS Severely impeded the elucidating of molecular mechaniSmS underlying diSeaSe development. Generation of induced pluripotent Stem cellS (iPSCS) by over-expreSSion of defined tranScription factorS in Somatic cellS, in particular in thoSe from patient Somatic cellS, preSentS an attractive and promiSing approach to model the early StageS of diSeaSeS in vitro and to Screen novel biomarkerS aS well aS therapeutic medicineS. Recently, many reSearch groupS have independently reported that patient-Specific iPSC-derived cellS recapitulated multiple featureS of pathological eventS of a particular diSeaSe, offering experimental evidence of utilizing patient-Specific iPSCS to model diSeaSeS and reevaluate the current therapieS. We have derived iPSC lineS uSing Somatic cellS of patientS Suffering from Klinefelter'S Syndrome (KS) and Alzheimer'S DiSeaSe (AD) and explored the poSSibility to uSe theSe iPSC lineS to recapitulate the pathological featureS of the diSeaSeS. Our reSultS Show that patient'S Specific iPSC lineS provide good opportunity to Study the development and treatment of diSeaSeS.
崔大伟：HSp90α是一种新的肿瘤标志物
肿瘤标志物是一类反映肿瘤存在的物质，在肿瘤患者体内的含量远远超过健康人群。与其他肿瘤检测手段相比，肿瘤标志物更加方便快捷，成本也大大降低，现已成为肿瘤诊断、预后及治疗指导中的重要辅助手段。至今尚无我国自主发现的肿瘤标志物在临床中被广泛应用和认可。
人热休克蛋白90α（HSp90α）是热休克蛋白家族中的重要成员，广泛存在于从细菌到哺乳动物的各类细胞中。清华大学罗永章教授课题组在世界上首次报道了肿瘤细胞特异分泌HSp90α的调控机理，同时首次揭示了细胞外HSp90α与细胞内HSp90α的分子差异，并进一步证明了分泌型HSp90α能促进肿瘤侵袭及转移，且其在血液中的含量与肿瘤恶性程度正相关。该课题组经过多年攻关，解决了一系列技术难题，成功研发出了性能稳定的“HSp90α定量检测试剂盒”，并完成了世界上首个HSp90α作为肿瘤标志物的临床试验，成功证明了HSp90α是肺癌相关肿瘤标志物，可用于患者病情监测和疗效评价。
该成果是抗肿瘤蛋白质药物国家工程实验室的一项重要成果，为产学研结合的科研运行模式树立了一个成功典范。
SRNA InduceS the Large-Scale TranSdetermination of MeSenchymal Stem CellS into Hematopoietic Stem CellS in Human.
MeSenchymal Stem cellS (MSCS) can differentiate into cellS of bone, endothelium, adipoSe tiSSue, cartilage, muScle, and brain. However, whether they can tranSdeterminate into hematopoietic Stem cellS (HSCS) remainS unSolved. We report here that a Subpopulation of human MSCS that are CD44+,CD29+, CD105+, CD166+,CD133-,CD34- could differentiate into hematopoietic Stem cellS (CD150+/CD133+/CD34+) and their deScending blood cellS in vitro, when tranSfected with new endogenouS ShRNAS The SRNA waS high-effectively delivered into MSCS by a novel peptide meanS. TheSe induced MSC-HSCS could form different typeS of hematopoietic colonieS aS nature-occurring HSCS did. Upon tranSplantation into Sublethally irradiated NOD/SCID mice, theSe MSC-HSCS engrafted and differentiated into all hematopoietic lineageS Such aS erythrocyteS, lymphocyteS, myelocyteS and thrombocyte. More importantly, theSe induced HSCS could SucceSSfully engraft and effectively function in patientS with Severe aplaStic anemia. Furthermore, we demonStrated the firSt evidence that the tranSdetermination of MSCS waS induced by acetylation of hiStone proteinS and activation of many tranScriptional factorS. Together, our findingS identify the SRNAS that dictateS a directed differentiation of MSCS toward HSCS and open up a new Source for HSCS uSed for the treatment of blood diSeaSeS and artificial Stem cell-made blood.
GE公司HiS标签蛋白纯化预装柱HiSTrap™ FF Crude使用技巧
主要介绍了HiS标签蛋白纯化预装柱HiSTrap™ FF Crude的实验过程，原理，说明，一般事项，样品制备，纯化操作， 按比例放大， 柱的清洗及保存等。
SIMDOL健康云服务及可穿戴医疗设备
自主知识产权、技术领先、专业门槛；创新的医疗健康管理模式：团队二三十年行业经验，稀缺资源；开放的服务平台；适用亿万级用户市场规模；持续增值的专业管理方法（模型）。中国至少有3~5亿适用人群，若以20%的市场购买率作为目标市场预测，将会有上亿规模的客户市场。本项目保守预测增速在60%以上，达产后的营收可达数亿元。
Herceptin BioSimilar GB221（1）
本课程主要讲述了Herceptin BioSimilar GB221在澳大利亚的1期临床试验的试验背景，相似性研究结果：N-端序列分析，C-端系列分析，色谱分析，等电点，SE-HPLC纯度比较，CE-SDS纯度比较，CEX电荷异构体比较，N-糖分析和比较，亲和力比较，对BT474细胞增殖抑制作用，GB221体外活性比较，GB221药物作用机制研究等一系列知识讲座。
immunotherapy againSt cancerS(poSition of Sellular therapy)
Study the pathological featureS of diSeaSeS uSing induced pluripotent Stem cellS derived form patient'S Somatic cellS
The limited experimental acceSS to diSeaSe-affected human tiSSueS haS Severely impeded the elucidating of molecular mechaniSmS underlying diSeaSe development. Generation of induced pluripotent Stem cellS (iPSCS) by over-expreSSion of defined tranScription factorS in Somatic cellS, in particular in thoSe from patient Somatic cellS, preSentS an attractive and promiSing approach to model the early StageS of diSeaSeS in vitro and to Screen novel biomarkerS aS well aS therapeutic medicineS. Recently, many reSearch groupS have independently reported that patient-Specific iPSC-derived cellS recapitulated multiple featureS of pathological eventS of a particular diSeaSe, offering experimental evidence of utilizing patient-Specific iPSCS to model diSeaSeS and reevaluate the current therapieS. We have derived iPSC lineS uSing Somatic cellS of patientS Suffering from Klinefelter'S Syndrome (KS) and Alzheimer'S DiSeaSe (AD) and explored the poSSibility to uSe theSe iPSC lineS to recapitulate the pathological featureS of the diSeaSeS. Our reSultS Show that patient'S Specific iPSC lineS provide good opportunity to Study the development and treatment of diSeaSeS.
New TrendS in RNA-Seq
来自Illumina China的测序产品经理余菽亮，分别从以下几个方面做了详细介绍： 在RNA序列的新的趋势，RNA序列的好处，RNA序列的挑战RNA序列的进化，TruSeq Standed RNA dUTP method ，提供完整的rRNA转录覆盖更多还原，TruSeq @ RNA库准备概述，单细胞测序的方法个别肿瘤细胞的转录组分析，细胞类型特异性基因表达标记，Fluidigm单细胞自准备系统概述等。